Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kyorin Holdings President Pledges to Hit Midterm Management Targets; Desalex Performs Better-Than-Expected
August 9, 2018
- Sumitomo Dainippon Chief Rules Out Divestment of Cash-Cow LLPs
August 8, 2018
- Maviret Remains Japan’s Best-Selling Drug in April-June: IQVIA
August 8, 2018
- Ethical Drug Sales Down 4.6% in June: Crecon
August 8, 2018
- Drug Wholesalers Log Sluggish Price Settlement Rates as They Run Careful Negotiations under New Guidelines
August 7, 2018
- Japan Lifestyle-Related Disease Treatment Market to Subside, after Peaking in 2018: Fuji Keizai
August 7, 2018
- AnGes’ HGF Therapy Could Debut Before Year-End to Become 1st Gene Therapy in Japan; 2 More Products Anticipated in 2019
August 7, 2018
- Takeda, Whiz Partners to Set Up Joint Investment Fund to Spur Drug Ecosystem
August 6, 2018
- Amgen Astellas Seeks OK for Repatha Monotherapy Use in Statin-Intolerant Patients
August 6, 2018
- Rituxan Filed for Add’l Indication of Chronic Lymphocytic Leukemia
August 6, 2018
- Opdivo Defended Crown with Ono’s Asia Sales Added, but Keytruda Triumph Would Come Soon
August 6, 2018
- AstraZeneca’s Japan Crestor Sales Dive 71%
August 3, 2018
- Ninlaro Production Site Opens in Russia: Takeda
August 3, 2018
- Thrombocytopenia Drug Mulpleta Earns FDA Approval: Shionogi
August 3, 2018
- Recomodulin Fails to Hit Primary Goal in PIII for Severe Sepsis with Coagulopathy: Asahi Kasei
August 3, 2018
- Eisai Neurology Chief Shows Eagerness on Alzheimer’s Combination Trials
August 2, 2018
- AstraZeneca’s AI Translation System Could Bring Huge Impact If Materialized: Japan R&D Chief
August 2, 2018
- Opdivo Sales Up 15% in April-June: Ono
August 2, 2018
- Daiichi Sankyo’s FLT3 Inhibitor Grabs FDA’s Breakthrough Therapy Status
August 2, 2018
- Kyowa Kirin Hopeful of PIII Study of Sakigake Designated DKD Treatment: President
August 2, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…